The reverse translation of a quantitative neuropsychiatric framework into preclinical studies: Focus on social interaction and behavior.


Journal

Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090

Informations de publication

Date de publication:
02 2019
Historique:
received: 10 12 2017
revised: 29 05 2018
accepted: 27 07 2018
pubmed: 21 1 2019
medline: 30 6 2019
entrez: 21 1 2019
Statut: ppublish

Résumé

Following the Research Domain Criteria (RDoC) concept, major brain circuits are conserved in evolution and malfunctioning of a brain circuit will lead to specific behavioral symptoms. Reverse translation of patient-based findings from Alzheimer's disease (AD), schizophrenia (SZ) and major depression (MD) patients to preclinical models accordingly can be a starting point for developing a deeper understanding of the functional circuit biology and contribute to the validation of new hypotheses for therapeutic intervention in patients. In the context of the EU funded PRISM project, a preclinical test battery of tasks has been selected and aligned with the clinical test battery. It allows for assessment of social functioning, sensory processing, attention and working memory and is designed for validation of biological substrates from human molecular landscaping of social withdrawal. This review will broadly summarize the available literature on tasks for studying social behavior in rodents and outline the development of a preclinical test battery for the PRISM project by reverse translation.

Identifiants

pubmed: 30660427
pii: S0149-7634(17)30919-3
doi: 10.1016/j.neubiorev.2018.07.018
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

96-111

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Tatiana Peleh (T)

Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Diseases, Birkendorfer Straße 65, 88397, Biberach an der Riss, Germany. Electronic address: tatiana.peleh@boehringer-ingelheim.com.

Kevin G O Ike (KGO)

Groningen Institute for Evolutionary Life Sciences (GELIFES), University of Groningen, Nijenborgh 7, 9747 AG, Groningen, The Netherlands. Electronic address: k.g.o.ike@rug.nl.

Emma J Wams (EJ)

Groningen Institute for Evolutionary Life Sciences (GELIFES), University of Groningen, Nijenborgh 7, 9747 AG, Groningen, The Netherlands. Electronic address: e.j.wams@rug.nl.

Evan P Lebois (EP)

Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA, 02139, USA. Electronic address: Evan.P.Lebois@pfizer.com.

Bastian Hengerer (B)

Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Diseases, Birkendorfer Straße 65, 88397, Biberach an der Riss, Germany. Electronic address: bastian.hengerer@boehringer-ingelheim.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH